The Immunopathogenesis of uveitis.

Area of Science:

• Ophthalmology and Immunology
• Ocular Inflammation and Immune Privilege
• Immunopathogenesis of Uveitis

Background:

• Uveitis is a leading cause of preventable blindness, stemming from immune system dysregulation within the eye.
• Ocular immune privilege is maintained by physical barriers, local immunosuppression, and systemic tolerance mechanisms.
• Failure of these regulatory mechanisms can lead to various forms of uveitis, including autoimmune, autoinflammatory, infectious, and paraneoplastic.

Purpose of the Study:

• To elucidate the complex immunopathogenesis of uveitis, encompassing autoimmune, autoinflammatory, infectious, and paraneoplastic etiologies.
• To highlight the role of genetic susceptibility, T-cell responses, B-cell involvement, and innate pathways in uveitis development.
• To correlate mechanistic understanding with therapeutic strategies for different uveitis subtypes.

Main Methods:

• Review of existing literature and animal models (e.g., experimental autoimmune uveitis) to define ocular immune regulation and disease pathways.
• Analysis of genetic factors (HLA, ERAP), cellular players (T-cells, B-cells, microglia, macrophages), and molecular mediators (cytokines, inflammasomes).
• Extrapolation of findings from experimental models to human uveitis pathogenesis and therapeutic approaches.

Main Results:

• Autoimmune uveitis involves genetic predisposition, T-cell activation (Th1/Th17), and inflammatory cascades amplified by myeloid cells.
• Infectious and post-infectious uveitis result from direct infection or immune responses mimicking pathogens.
• Autoinflammatory uveitis is driven by innate immune pathway dysregulation (inflammasome/IL-1), while paraneoplastic uveitis involves anti-tumor immunity cross-reactivity.
• Tissue-resident memory T-cells may contribute to uveitis relapse.

Conclusions:

• Therapeutic strategies for uveitis must be tailored to the underlying immunopathology, targeting specific immune pathways.
• Antimicrobials are crucial for infectious uveitis, followed by anti-inflammatory treatment.
• Steroid-sparing agents targeting TNF and IL-6, or IL-1 blockade, are effective for autoimmune and autoinflammatory uveitis, respectively.
• Advances in humanized modeling are essential for refining condition-specific treatments.